Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haleos LabsBOM:540679 68 ROC (Joel Greenblatt) % is 6.24% as of Jun. 2026, which is 47% below its 10-year median of 11.88. GuruFocus rates BOM:540679 with a GF Score™ of 68/100 and a GF Value™ of ₹1,147.25 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,324 Biotechnology companies, Haleos Labs ranks better than 83.99% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Haleos Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 6.24%.
The historical rank and industry rank for Haleos Labs's ROC (Joel Greenblatt) % or its related term are showing as below:
BOM:540679'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.55 Med: 11.88 Max: 23.36
Current: 8.88
During the past 11 years, Haleos Labs's highest ROC (Joel Greenblatt) % was 23.36%. The lowest was 6.55%. And the median was 11.88%.
BOM:540679's ROC (Joel Greenblatt) % is ranked better than 83.99% of 1324
companies
in the Biotechnology industry
Industry Median: -306.72
vs BOM:540679: 8.88
Haleos Labs's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -8.90% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Haleos Labs ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Haleos Labs's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540679 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Haleos Labs's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Haleos Labs's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 6.24% mean?
Haleos Labs (BOM:540679) has a ROC (Joel Greenblatt) % of 6.24% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Haleos Labs and its competitors. This is 47% below median its historical median of 11.88. Over the past decade, Haleos Labs' ROC (Joel Greenblatt) % has ranged from 6.55 to 23.36. According to the industry distribution chart, Haleos Labs ranks #212 out of 1324 companies in the Biotechnology industry, placing it in the top 16%.
Is Haleos Labs' ROC (Joel Greenblatt) % too high?
Haleos Labs' current ROC (Joel Greenblatt) % of 6.24% is 47% below median its 10-year median of 11.88. Over the past 10 years, this metric has ranged from a low of 6.55 to a high of 23.36. Based on the distribution chart, Haleos Labs ranks #212 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Haleos Labs has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #212 out of 1324 companies for ROC (Joel Greenblatt) %. This places Haleos Labs in the top 16% of its industry — outperforming the majority of peers. Historically, Haleos Labs' own ROC (Joel Greenblatt) % has ranged from 6.55 to 23.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Haleos Labs and its competitors. Haleos Labs's current ROC (Joel Greenblatt) % is 6.24%, which is 47% below median its own 10-year median of 11.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (BOM:540679) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,147.25, compared to a current price of ₹1,490.30 — trading 29.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is 6.24%, which is 47% below median its 10-year median of 11.88. Haleos Labs' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Haleos Labs (BOM:540679), the current ROC (Joel Greenblatt) % is 6.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (BOM:540679) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,490.30 is trading 29.9% above its estimated GF Value™ of ₹1,147.25.
GuruFocus considers Haleos Labs to be Modestly Overvalued.
Key valuation signals for BOM:540679:
ROC (Joel Greenblatt) %: 6.24% (47% below median its 10-year median of 11.88)
GF Value™: ₹1,147.25 vs. price of ₹1,490.30 (29.9% above fair value)
No single metric tells the full story. See the BOM:540679 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
68GF Score
Get the complete analysis for BOM:540679
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540679 has been successfully added to your 
